REGULATORY

1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition

June 15, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

First generic versions for 13 APIs (252 products) including those for major brands Micardis (telmisartan) and Abilify (aripiprazole) will be added to the NHI reimbursement price list on June 16, the Ministry of Health, Labor and Welfare (MHLW) announced in…

To read the full story

Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
Talion AG, 2 Other APIs Skip December Gx Listing
December 8, 2016

REGULATORY

Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…